Switching to Faricimab in Neovascular Age-related Macular Degeneration Resistant to Both Aflibercept and Ranibizumab

Inclusion criteria * Presence of neovascular age-related macular degeneration (AMD) in the study eye * Previous treatment with minimum 6 consecutive, monthly aflibercept (Eylea®) injections in the study eye without optimal treatment response, defined as persisting intraretinal fluid or subretinal fluid or both on optical coherence tomography scans * Subsequently, a sequential switch to ranibizumab (Lucentis®), with minimum 1 injection, also without optimal response * Finally, a sequential treatment switch from ranibizumab to faricimab. Exclusion criteria * Neovascular conditions other than AMD (e.g., choroidal neovascularisation due to other causes) or co-existence of other retinal disease in the study eye * Significant optical media opacities that would result in poor imaging quality on OCT scans in the study eye * Intraocular surgery in the study eye 3 months before or within 1 month after the treatment switch